Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips

Summary:

  • It’s always and forever a market of stocks, not a stock market. The Nasdaq is up 45% YTD, while Pfizer Inc. stock is down 40%.
  • Pfizer’s yield is at 14-year highs, nearly 30% undervalued. The collapse in earnings this year is pure pandemic vaccine boom fading.
  • Pfizer’s long-term growth prospects are slightly better than the industry average, though it is growing 6X slower than Eli Lilly, which is powered by obesity drugs.
  • In the medium term, patent cliffs on key drugs mean Pfizer is being left for dead in favor of its obesity drug-powered rivals. If you’re comfortable with its risk profile, Pfizer offers Warren Buffett-like 22% annual returns over the next 2 years.
  • For those who don’t like Pharma or want superior yield, growth, and over 300% better long-term return potential than Pfizer, these five 9%-yielding blue-chip bargains are a fantastic opportunity to lock in as much as 150% returns in just the next two years, 7.5X more than the S&P 500.

Money rain. Yes I did it! Portrait of joyous winner, young woman in casual shirt standing with clenched fists and closed eyes, celebrating victory and richness.

Khosrork

The market is red hot this year…or is it?

The S&P 500 (SP500) is up almost 20%, and the Nasdaq 100 (NDX) almost 50%. But in reality, the S&P equal weight is only up 4%.

It’s the

Screening Criteria Companies Remaining % Of Master List
1 Blue-Chip Quality (10, 11, 12, and 13 quality scores) 467 93.40%
2 BHS Rating “reasonable buy, good buy, strong buy, very strong buy, ultra value buy” 345 69.00%
3 Non-Speculative (No Turnaround Stocks, investment grade) 303 60.60%
4 5.5+% Yield 31 6.20%
5 11+% Long-Term Return Potential 18 3.60%
6 5 highest yielding PFE alternatives 5 1.00%
Total Time 1 minute


Analyst’s Disclosure: I/we have a beneficial long position in the shares of BTI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


—————————————————————————————-

Dividend Kings helps you determine the best safe dividend stocks to buy via our Automated Investment Decision Tool, Zen Research Terminal, Correction Planning Tool, and weekly screening videos. 

Membership also includes

  • Access to our 13 model portfolios (all of which are beating the market in this correction)

  • my family’s $2.5 million charity hedge fund 

  • 50% discount to iREIT (our REIT-focused sister service)

  • real-time chatroom support

  • real-time email notifications of all my retirement portfolio buys

  • numerous valuable investing tools

Click here for a two-week free trial, so we can help you achieve better long-term total returns and your financial dreams.

Leave a Reply

Your email address will not be published. Required fields are marked *